| Literature DB >> 30342839 |
Michaela E Johnson1, Benjamin Stecher2, Viviane Labrie3, Lena Brundin3, Patrik Brundin4.
Abstract
We hypothesize that Parkinson's disease (PD) pathogenesis can be divided into three temporal phases. During the first phase, 'triggers', such as viral infections or environmental toxins, spark the disease process in the brain and/or peripheral tissues. Triggers alone, however, may be insufficient, requiring 'facilitators' like peripheral inflammation for PD pathology to develop. Once the disease manifests, 'aggravators' spur further neurodegeneration and exacerbate symptoms. Aggravators are proposed to include impaired autophagy and cell-to-cell propagation of α-synuclein pathology. We believe clinical trials need to consider these three phases and target potential therapies at the appropriate stage of the disease process in order to be effective.Entities:
Keywords: Parkinson’s disease; clinical trials; genetics; inflammation; α-synuclein
Mesh:
Substances:
Year: 2018 PMID: 30342839 PMCID: PMC6623978 DOI: 10.1016/j.tins.2018.09.007
Source DB: PubMed Journal: Trends Neurosci ISSN: 0166-2236 Impact factor: 13.837